• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [224 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabotegravir (HIV-1 infection in adolescents) – Benefit assessment according to §35a Social Code Book V]
2024 NIHR Health Technology Assessment programme Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding universal screening for congenital cytomegalovirus (CMV) infection to Québec newborn screening program]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: genital herpes - identification, diagnosis, optimal use of antivirals and follow-up]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Blood determination of a panel of anti-tuberculosis drugs using a multiplex approach by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) in the context of clinical pharmacometrics]
2024 Agency for Care Effectiveness (ACE) Cabotegravir with rilpivirine for treating human immunodeficiency virus type 1 (HIV-1) infection
2024 Institute of Health Economics (IHE) Current and future investments for reaching the UNAIDS 95-95-95 HIV targets in Canada: evidence review & cost analysis
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Syphilis - detection, diagnosis, optimal antibiotic use, and follow-up]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bictegravir/ emtricitabine/ tenofovir alafenamide (HIV infections in children and adolescents) - Benefit assessment according to § 35a SGB V]
2023 Austrian Institute for Health Technology Assessment (AIHTA) Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patient/social, ethical and legal elements
2023 Austrian Institute for Health Technology Assessment (AIHTA) [Sponsoring of patient initiatives in Austria. 5th update of the systematic analyses 2014 to 2019]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/abacavir/lamivudine (HIV infection in children) - Benefit assessment according to §35a Social Code Book V]
2023 NIHR Health Services and Delivery Research programme The effectiveness of sexual assault referral centres with regard to mental health and substance use: a national mixed-methods study – the MiMoS Study
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis by NAAT]
2022 NIHR Public Health Research (PHR) programme E-health interventions targeting STIs, sexual risk, substance use and mental health among men who have sex with men: four systematic reviews
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection in adolescents) - Benefit assessment according to §35a Social Code Book V]
2022 Agency for Care Effectiveness (ACE) Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
2022 National Institute for Health and Care Excellence (NICE) Cabotegravir with rilpivirine for treating HIV-1. NICE technology appraisal guidance 757
2021 NIHR Health Technology Assessment programme A randomized controlled trial to study the effectiveness of laser ablation versus observation to prevent anal cancer in men with human immunodeficiency virus who have high-grade anal intraepithelial neoplasia
2021 The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice Vocabria® and Rekambys® for the treatment of HIV-1 infection
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibalizumab (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection in children aged >= 4 weeks to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabotegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020 Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use of immunoglobulins in hematology]
2020 National Committee for Technology Incorporation (CONITEC) [Dolutegravir for the treatment of pregnant women living with HIV]
2020 Malaysian Health Technology Assessment (MaHTAS) Programmatic management of latent tuberculosis infection
2020 Agency for Care Effectiveness (ACE) Antiretroviral therapies for treating human immunodeficiency virus type 1 (HIV-1) infection
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cobicistat (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies
2019 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Sponsoring of Patient Initiatives in Austria 2018. Update of the Systematic Analyses 2014, 2015 and 2016
2019 Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use guide: pharmacological treatment of sexually transmitted and blood-borne infections ─ external condylomas (anogenital warts)]
2019 Institute for Clinical Effectiveness and Health Policy (IECS) [Selexipag in pulmonary hypertension]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019 Health Information and Quality Authority (HIQA) Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Tenofovir alafenamide in patients with HIV diagnosis]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bictegravir/emtricitabine/tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bictegravir/emtricitabine/tenofovir alafenamide (HIV infection) - Addendum to Commission A18-43]
2017 NIHR Health Technology Assessment programme The clinical effectiveness of individual behaviour change interventions to reduce risky sexual behaviour after a negative human immunodeficiency virus test in men who have sex with men: systematic and realist reviews and intervention development
2017 NIHR Health Services and Delivery Research programme REACH: a mixed-methods study to investigate the measurement, prediction and improvement of retention and engagement in outpatient HIV care
2017 Institute for Clinical Effectiveness and Health Policy (IECS) [Posaconazole for invasive fungal infection treatment and prevention in neutropenic patients]
2017 Institute for Clinical Effectiveness and Health Policy (IECS) [Efavirenz, Emtricitabine and Tenofovir (Simplir®) in HIV infection – comparison with other brands in Argentina]
2017 Institute for Clinical Effectiveness and Health Policy (IECS) [Atazanavir/cobicistat (Evotaz®) in HIV infection]
2017 Institute for Clinical Effectiveness and Health Policy (IECS) [Dolutegravir, Abacavir and Lamivudine (Triumeq®) in HIV infection]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection) - Addendum to commission A17-11]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2016 NIHR Health Technology Assessment programme BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial
2016 Haute Autorite de sante (HAS) [Evaluation of gene amplification for diagnosis Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster) in people living with HIV]
2016 NIHR Health Technology Assessment programme The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection
2016 Agency for Healthcare Research and Quality (AHRQ) Strategies for improving the lives of women aged 40 and above living with HIV/AIDS.
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine (new therapeutic indication): addendum to commisison A15-55]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: addendum to commission A15-61]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/tenofovir alafenamide (HIV) - Addendum to Commission A16-30]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a SGB V]
2015 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Dolutegravir/abacavir/lamivudine (Triumeq®)
2015 Institute for Clinical Effectiveness and Health Policy (IECS) [Assessment on nucleic acid amplification techniques (NAT) for human immunodeficiency, hepatitis C and hepatitis B virus screening in blood banks]
2015 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Darunavir (Prezista®)
2015 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rarunavir/cobicistat (Rezolsta®)
2015 Institute for Clinical Effectiveness and Health Policy (IECS) [Raltegravir for the treatment of human immunodeficiency virus infection]
2015 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®)
2015 Haute Autorite de sante (HAS) [Interferon-gamma release assays as in vitro screening tests for latent tuberculosis infection]
2014 NIHR Health Technology Assessment programme Effectiveness and cost-effectiveness of traditional and new partner notification technologies for curable sexually transmitted infections: observational study, systematic reviews and mathematical modelling
2014 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Darunavir (Prezista®)
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Direct acting antivirals for chronic hepatitis C genotype 1 in select populations: emerging evidence of clinical effectiveness and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Conjugate pneumococcal vaccine (13-Valent) for immunocompromised populations: a review of the clinical evidence
2014 NIHR Health Services and Delivery Research programme A systematic review of the effectiveness and cost-effectiveness of peer-based interventions to maintain and improve offender health in prison settings
2014 Norwegian Knowledge Centre for the Health Services (NOKC) Gynecological consequences of female genital mutilation/cutting (FGM/C)
2014 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Emtricitabine/rilpivirine/tenofovir disoproxil (as fumarate) (Eviplera®)
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Nabilone for non-chemotherapy-associated nausea and weight loss due to medical conditions: a review of the clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Dolutegravir (Tivicay — ViiV Healthcare ULC) indication: HIV infection
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Direct acting antivirals for chronic hepatitis C genotype 1 in select populations: emerging evidence of clinical effectiveness and safety
2014 Malaysian Health Technology Assessment (MaHTAS) Rapid blood test device for HIV, HBV, HCV, &amp; syphillis
2014 Malaysian Health Technology Assessment (MaHTAS) Enercel homeopathic medicine for patient with infectious diseases and motor neuron disease
2014 Basque Office for Health Technology Assessment (OSTEBA) [Sperm washing in serodiscordant HIV couples for use in assisted human reproduction techniques]
2014 Andalusian Health Technology Assessment Area (AETSA) [Summary of evidence for efficacy and safety of sofosbuvir in patients with chronic hepatitis c coinfected with human immunodeficiency virus]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug combination of emtricitabine, rilpivirine and tenofovir disoproxil (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/abacavir/lamivudine - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Darunavir (Prezista®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tenofovir disoproxil fumarate (Viread®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Etravirine (Intelence®)
2013 Penn Medicine Center for Evidence-based Practice (CEP) Guidelines for initiating antiretroviral therapy in hospital inpatients with HIV
2013 Canadian Agency for Drugs and Technologies in Health (CADTH) Group care for chronic disease management: a review of the clinical effectiveness, cost-effectiveness, and guidelines